RhumbLine Advisers’s HUTCHMED HCM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$61.3K Buy
4,096
+64
+2% +$936 ﹤0.01% 3551
2025
Q4
$53.7K Buy
4,032
+1,275
+46% +$18.6K ﹤0.01% 3622
2025
Q3
$43.4K Sell
2,757
-271
-9% -$4.46K ﹤0.01% 3679
2025
Q2
$45.6K Sell
3,028
-272
-8% -$3.98K ﹤0.01% 3683
2025
Q1
$49.6K Sell
3,300
-4,499
-58% -$66.5K ﹤0.01% 3578
2024
Q4
$112K Buy
7,799
+90
+1% +$1.61K ﹤0.01% 3447
2024
Q3
$151K Buy
7,709
+156
+2% +$2.82K ﹤0.01% 3366
2024
Q2
$129K Buy
7,553
+564
+8% +$10.4K ﹤0.01% 3435
2024
Q1
$117K Buy
6,989
+79
+1% +$1.2K ﹤0.01% 3389
2023
Q4
$125K Sell
6,910
-1,194
-15% -$21.7K ﹤0.01% 3374
2023
Q3
$137K Hold
8,104
﹤0.01% 3351
2023
Q2
$97.2K Buy
+8,104
New +$111K ﹤0.01% 3531

Other funds holding HCM

RhumbLine Advisers's HCM Position: Q1 2026 in Review

RhumbLine Advisers increased its HUTCHMED (HCM) stake by 1.6% in Q1 2026, buying an estimated $936 and bringing the position to 4,096 shares worth $61.3K. The position accounts for ﹤0.01% of the portfolio, ranked #3551.

RhumbLine Advisers first reported a position in HCM in Q2 2023 and has held it in 12 quarters since. The position peaked at $151K in Q3 2024. 54 funds tracked by Wall St. Rank hold HCM as of Q1 2026.

  • RhumbLine Advisers held 4,096 shares of HUTCHMED worth $61.3K as of Q1 2026.
  • RhumbLine Advisers bought 64 HUTCHMED shares in Q1 2026, an estimated $936.
  • HUTCHMED made up ﹤0.01% of RhumbLine Advisers's portfolio in Q1 2026, its #3551 holding.
  • RhumbLine Advisers first reported a position in HUTCHMED in Q2 2023 and has held it in 12 quarters since.
  • RhumbLine Advisers's HUTCHMED position peaked at $151K in Q3 2024.
  • 54 funds tracked by Wall St. Rank held HUTCHMED as of Q1 2026.

Based on RhumbLine Advisers's 13F filing for Q1 2026, filed 12 May 2026.